|Tested species reactivity||Rat|
|Published species reactivity||Rat|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Rat thymocyte membrane|
|Storage buffer||PBS with 4-5mg/ml BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||0.5 ug/10^6 cells|
|Immunofluorescence (IF)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
MA5-17391 targets CD4 in FACS and IF applications and shows reactivity with Rat samples.
The MA5-17391 immunogen is rat thymocyte membrane.
The CD4 antigen is involved in the recognition of the type II MHC antigen. It is also a receptor for HIV. It is present on most T helper cells and normal thymocytes. The cytoplasmic portion of CD4 is associated with p56lck tyrosine kinase. CD4 expression is commonly found in human lymph nodes and tonsils. CD27 (50 kDa) is a member of the tumor necrosis factor (TNF) receptor superfamily. CD40 and CD30 are also members of the TNF receptor superfamily. The TNF superfamily members are known for the regulation of cell proliferation and death. In contrast to the expression of other TNFR/TNF family members, expression of CD27 and its ligand CD70 is predominantly confined to lymphocytes. High expression levels of CD27 appear to be dependent on proper ligation of antigen receptors. CD70 expression requires additional co-stimulatory and/or pro-inflammatory signals. CD27 is a membranebound receptor, but a soluble form of CD27 is also produced.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms.
MA5-17391 was used in flow cytometry to test if RAGE contributes to B cell mediated, T cell-dependent autoimmune diseases such as myasthenia gravis.
|Mu L,Zhang Y,Sun B,Wang J,Xie X,Li N,Zhang J,Kong Q,Liu Y,Han Z,Wang G,Fu Z,Yu B,Li G,Li H||Clinical immunology (Orlando, Fla.) (141:36)||2011|